Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
   Trial
2. [Malaria in 2022: clinical and therapeutic aspects].Medecine tropicale et sante internationale · 2023
   Article
3. Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?The Lancet. Infectious diseases · 2022
   Article

Corrections and comments

• Commented on by
  Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?2022
• Comment on
  Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.2022

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as